Member Info for Kaeren

B2HS2L , I am happy to post my questions on the board next week , will contemplate at weekend. We must however be mindful that the posters on this board represent a relatively small % of overall holders and therefore the company not addressing certain questions raised is not neccessarily a refusal to do so , the questions may not be the most popular ones. For example Tata related questions , non bb readers may not even be aware of any connection .

The RNs dated the 25th Jan was quite clear in outlining some key elements of the strategy going forwards. It lacked specific detail but contained within it we are told ".... and intends to expand further on the strategy at the time of it's full 2021 results"
We were told amongst many other things that success would be measured differently , shift from being development led to market led , number of products irrelevant , developing solutions to meet customer needs key.
Streamling R&D to ensure keenly focused on commercially attractive opportunities.
Invest in non-covid -19 product development to tackle un met market needs.
Evaluate how to leverage our products in each of target global markets.
This is just a snippet , we were also informed Novacyt had begun to implement several of the key findings from D.A 's review.
I am in no doubt we will be given much more detail about the strategy going forwards because we have been told that is what will take place in the RNS dated 25th of Jan.
So roll on next week.

Saint , without doubt they use our instruments and as of Feb those supplied were manufactured in the UK. The big money earner is utilising our tests to use on those machines. Thanks to your research on Tata1mg have seen via linked in that they too avail of our machines. Numbers not known.
What I would like to know is the following, is there any planned pipeline of supply of non covid tests , is it happening already ? Are the R&D team working on converting RUO tests for TATAMD and TATA1mg to use ? Or any other specific tests they have requested. If we are not , then we are limiting our earning capacity by supplying our instruments to them in preference to other customers.
In other words why supply our instruments for Tata to use other companies tests on.

I will submit some questions in advance and on the day any that may arise from the contents of the presentation. After six months at the helm there should not be any questions the CEO is not competent enough to answer. ChasPB I don't know what you hope to achieve by advocating that approach , they will only select those questions they want to answer. This is no different to any other company.

Small detail that shows they are listening. French subtitles. Think that it is a great addition.

Thx hadn't seen that one , don't focus on Microgen at all. Put two up on Twitter over bank hols , one Equine, one Tick and saw porcine study too.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8802959/

Thought they might have been in that army tender I posted in March as several M. Bioproduct tests in it , but alas nada I recognise as being the same.

So unless we learn otherwise Larry , it would appear that the test dates to 2017 but according to the lists you posted seven batches have been produced and signed off throughout Feb 2022. I assume to fulfill an order , but no idea of costs or for whom. Thx for info. Will have a dig.

Not new just been informed.

I have no idea what this or if it is new ?
https://twitter.com/NovacytGroup/status/1516380342248222726?s=20&t=82wubCJcfBbvEiEfGy_A5A

But note Merke appear to have a similar test.
https://www.sigmaaldrich.com/IE/en/product/mm/100181

Another lab using ProMate accredited. Need as many instruments as possible in the market to execute initial master plan of Nova supplying the blades.
Over to you Dave.
https://twitter.com/KaerenH/status/1515844170560245776?s=20&t=82wubCJcfBbvEiEfGy_A5A

It's a strange form of commentary Valju , why doesn't she just post on the board. I dare say EUA holders aren't very thrilled at the musings. Each to there own style :)

Tata 1mg as pointed out by Saint Iast week is a new arm of Tata digital, not Tata MD whom we know is already using our instruments.
Tata 1mg on linked in confirming they too use our instruments.
https://twitter.com/Larry64450205/status/1516135138064744453?s=20&t=4fN8O1KHoU0O9MW2v8XO7Q

Thx Larry , Mark Coldwell , Head of scientific communication for a year. I haven't heard him communicate at all , perhaps it is internal , perhaps he communicates with distributors or customers.

Two 53k trades at 2.70 just gone thru on bourse , can't tell if one cancels the other out.

https://twitter.com/NovacytGroup/status/1514545256632627203?s=20&t=YeUOCjiCNu2z0Zf6oaPDPA

Youre a comedian BYP , the next new investor who looks in here will see more then Wilson's post , mirror reflection .

Yes if course it's good news , just like if it had failed it would be bad news. Idiot.

I'm not scared of saying anything negative , I often berate the lack of communication , the fact they don't make use of certain brands utilising their products.
Openly called out the individual who many viewed as a security blanket. As I invest and dont trade then yeah I prob will be here in several years. My choice. Same with another share I've taken a position in , my strategy has worked for me. I didn't call you out , you must have a large chip on your shoulder , enjoy carrying it around. Was born positive and hopefully will stay that way till I depart this mortal coil.

Dont trade , no idea if you do or dont hold BYP , I actually believe you do. I don't believe for a sec P100 does and dont give a flying monkey what you or he thinks. I'm a bloody weird trader to post consistently and positively. Perhaps I have a special market I sell to at midnight. You tool of the first degree.
To get another test certified is good news.
Wish I could generate the sums they will potentially make from something that's over.
You think you can spit your dummy , swear and abuse and concoct B /S . Two a penny in the city , bothered no !
No suprise Novacyt doesnt respond to you , I wouldn't.